genedrive PLC (LON:GDR) has said its coronavirus (COVID-19) testing technology will be sold in the US and Europe by partner Beckman Coulter Life Sciences, taking the pair’s previous collaboration agreement to the “next stage”.
The company said its 96 SARS-CoV-2 kit is ideally suited for use on Beckman’s high throughput robotic Biomek i7 instrument.
“The ready-to-go nature of the test removes many of the fluid dispensing steps required in competitor assays, increasing the overall throughput of the Biomek compared to using a liquid reagent-based test formulation,” investors were told.
The automated solution could process 1,000 PCR samples per workstation over a standard eight-hour day, requiring in the process the equivalent of just half a full-time technician.
"We are very pleased to have the partnership of Beckman Coulter in accessing significant COVID testing opportunities throughout the United States and Europe, where the incidence of COVID continues to escalate and the need for high throughout testing solutions remains a priority,” said genedrive chief executive David Budd in a statement.
“The combination of genedrive and Beckman Coulter products and expertise provides the company with a new, innovative, and competitive solution, and a new sales channel for the American market, which we did not have previously.
"We are very pleased to now take our initial collaboration and development agreement to the commercial stage. Beckman Coulter is an important and significant company in these core geographies, well suited to promoting, selling, and supporting our products," Budd added.
